Compounding pharmacists prepare individualized hormone formulations — including HCG, progesterone, and thyroid preparations — that are central to NaProTECHNOLOGY treatment protocols, where standardized commercial doses are often inadequate for patient-specific needs. Collaborative prescribing between NaPro practitioners and licensed compounding pharmacists ensures consistent bioidentical formulation quality, dosing precision, and regulatory compliance within fertility and reproductive endocrine management.
what is a compounding pharmacist in NaProTechnology, what does bioidentical hormone mean, difference between bioidentical and synthetic hormones, why are natural hormones not patented or FDA approved, does the WHI study apply to bioidentical hormones, how to find a compounding pharmacist, are compounded prescriptions covered by insurance, compounding pharmacy regulation Section 503A
Hilgers et al. 2004, Hilgers 2004
Cite this article
Hilgers, T. W., & Reed-Kane, D. (2004). Chapter 37: Role of Compounding Pharmacist. The Medical and Surgical Practice of NaProTECHNOLOGY, 467-476.
Hilgers TW, Reed-Kane D. Chapter 37: Role of Compounding Pharmacist. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:467-476.
Hilgers, T. W., and D. Reed-Kane. "Chapter 37: Role of Compounding Pharmacist." The Medical and Surgical Practice of NaProTECHNOLOGY, 2004, pp. 467-476.
Thomas W. Hilgers, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Medical protocols in NaProTECHNOLOGY are cycle-phase-targeted regimens — covering ovulation induction, luteal phase hormonal support, hyperprolactinemia management, thyroid optimization, and pre-conceptual supplementation — derived from the biomarker-defined diagnosis rather than empirical stimulation. Consolidating these protocols in a single reference enables practitioners to apply evidence-based, individualized treatment sequences that address root hormonal pathology while supporting natural conception.
Hilgers TW, 2004·The Medical and Surgical Practice of NaProTECHNOLOGY
Hilgers distinguishes isomolecular hormones -- molecules structurally identical to endogenous estradiol and progesterone -- from heteromolecular artimones, his term for synthetic analogues such as medroxyprogesterone acetate, norethindrone, and ethinyl estradiol, which differ in receptor binding, metabolic pathways, and systemic effects. NaProTECHNOLOGY restricts hormone therapy to isomolecular compounds administered in cycle-synchronized, physiologic doses because artimones suppress the hypothalamic-pituitary-ovarian axis, mask underlying pathology, and produce non-physiologic metabolite profiles incompatible with a restorative reproductive medicine approach.
The paper presents the main concepts of NaProTECHNOLOGY. Such problems as family planning effectiveness, targeted hormonal assessment of the menstrual cycle, ovarian hormone and target organ dysfunction, disorders of human ovulation, cooperative progesterone replacement therapy, premenstrual syndrome, postpartum depression, unusual bleeding, infertility and antiadhesion therapy are discussed.
The paper presents the main concepts of NaProTECHNOLOGY. Such problems as family planning effectiveness, targeted hormonal assessment of the menstrual cycle, ovarian hormone and target organ dysfucntion, disorders of human ovulation, cooperative progesterone replacement therapy, premustrual syndrome, postpartum depression, unusual bleeding, infertility and antiadhesion therapy are discussed.